A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease (CVD)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pelacarsen (Primary)
Indications Cardiovascular disorders; Hyperlipoproteinaemia; Myocardial infarction; Stroke
Focus Registrational; Therapeutic Use
Acronyms Lp(a)HORIZON
Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals

Most Recent Events

12 Feb 2025 Planned End Date changed from 30 May 2025 to 26 Feb 2026.
12 Feb 2025 Planned primary completion date changed from 29 May 2025 to 26 Feb 2026.
24 Aug 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight